Rubraca

maintenance therapy, Fallopian Tube Reanastomosis, Castration + 2 more
Treatment
20 Active Studies for Rubraca

What is Rubraca

RucaparibThe Generic name of this drug
Treatment SummaryRucaparib is a medication used to treat advanced ovarian cancer. It is a type of drug called a poly (ADP-ribose) polymerase (PARP) inhibitor, which works by blocking an enzyme that helps cancer cells repair their DNA. Rucaparib is approved to treat ovarian cancers with BRCA1 or BRCA2 genetic mutations, or tumors with high levels of homologous recombination deficiency (HRD) loss of heterozygosity (LOH). It is marketed in the US under the brand name Rubraca.
Rubracais the brand name
image of different drug pills on a surface
Rubraca Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rubraca
Rucaparib
2016
3

Effectiveness

How Rubraca Affects PatientsRucaparib is a medication used to treat cancer. It works by blocking an enzyme called poly (ADP-ribose) polymerase (PARP) that helps cancer cells repair their DNA. Rucaparib has been found to prevent tumour growth and when combined with other chemotherapy drugs, it can increase the effectiveness of treatment. Additionally, it can cause blood vessels to widen, which can help chemotherapy drugs get to the cancer cells more effectively.
How Rubraca works in the bodyRucaparib is a drug designed to fight cancer cells with a genetic defect called BRCA mutation. This mutation prevents the cells from using the normal process for repairing their DNA. Rucaparib blocks three proteins – PARP1, PARP2, and PARP3 – which are normally used in DNA repair. This traps the proteins on damaged DNA and prevents them from repairing it. The cell is then left with toxic DNA that can't be repaired and eventually leads to its death. In BRCA-deficient cells, this process is called synthetic lethality, where two non-lethal defects combine and cause

When to interrupt dosage

The measure of Rubraca is contingent upon the diagnosed condition. The quantity of dosage can be observed in the table below, contingent upon the method of administration.
Condition
Dosage
Administration
maintenance therapy
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Fallopian Tube Reanastomosis
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Pharmacotherapy
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Castration
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Recurrent Primary Peritoneal Cancer
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Rubraca Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Rucaparib may interact with Pulse Frequency
There are 20 known major drug interactions with Rubraca.
Common Rubraca Drug Interactions
Drug Name
Risk Level
Description
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Rucaparib.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Rucaparib.
Ozanimod
Major
Rucaparib may decrease the excretion rate of Ozanimod which could result in a higher serum level.
Rimegepant
Major
The serum concentration of Rimegepant can be increased when it is combined with Rucaparib.
9-aminocamptothecin
Minor
The metabolism of 9-aminocamptothecin can be decreased when combined with Rucaparib.
Rubraca Toxicity & Overdose RiskThe toxic dose and effects of overdosing on rucaparib are currently unknown.
image of a doctor in a lab doing drug, clinical research

Rubraca Novel Uses: Which Conditions Have a Clinical Trial Featuring Rubraca?

Twelve active studies are assessing the potential of Rubraca to treat Advanced Ovarian Cancer.
Condition
Clinical Trials
Trial Phases
Recurrent Primary Peritoneal Cancer
1 Actively Recruiting
Phase 1, Phase 2
maintenance therapy
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Castration
31 Actively Recruiting
Phase 1, Phase 2, Phase 3
Fallopian Tube Reanastomosis
0 Actively Recruiting

Rubraca Reviews: What are patients saying about Rubraca?

2.7Patient Review
9/10/2020
Rubraca for cancer of ovary in patient with BRCA mutation
Despite lowering my dosage twice, I'm still experiencing extreme fatigue, very little motivation, shortness of breath and dizziness.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rubraca

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long can you take Rubraca?

"Rucaparib is typically taken 2 months after the last dose of platinum chemotherapy. Treatment with rucaparib is continued as long as the drug is effective and the side effects are tolerable."

Answered by AI

Is Rubraca a chemo pill?

"The prescription medicine Rubraca is used in adults to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned and is responding to platinum-based chemotherapy."

Answered by AI

Can Rubraca cure cancer?

"While Rubraca is not officially approved to treat pancreatic cancer by the FDA, some doctors may prescribe it for this purpose based on Clinical studies which have shown the drug to be effecting treating pancreatic cancer in adults with BRCA genetic mutations who had received at two chemotherapy drugs previously."

Answered by AI

What is Rubraca used for?

"Rucaparib is used to treat ovarian, fallopian tube, peritoneal, and prostate cancers. It works by slowing or stopping the growth of cancer cells."

Answered by AI

Clinical Trials for Rubraca

Image of BAMF Health in Grand Rapids, United States.

AB001 for Prostate Cancer

18+
Male
Grand Rapids, MI
This study is designed to investigate the safety, tolerability, and effectiveness of a new treatment called AB001 in both 177Lu-PSMA naïve and 177Lu-PSMA experienced patients with advanced prostate cancer. AB001 targets a specific protein found on prostate cancer cells called prostate specific membrane antigen (PSMA) and delivers radioactive particles to kill the cancer cells. The primary goal of the study is to determine the safety profile of AB001 and how well patients tolerate the treatment. Researchers also aim to identify the best dose and schedule for further testing and clinical development. AB001 could be a promising treatment because it uses alpha particles, which are highly effective at damaging cancer cells while causing minimal harm to surrounding healthy tissue. This targeted approach is expected to result in fewer side effects compared to other types of radiation therapy. This Phase 1 study consists of two main parts: dose escalation and dose expansion. In the first part, researchers will test different doses of AB001 to find the safest and most effective dose. In the second part, the selected dose will be further evaluated to refine the treatment schedule and gather more data on its effectiveness and safety. The study aims to provide early data on the anti-tumour activity of AB001 and determine the best dose and treatment schedule for future trials. Researchers hope that AB001 will offer a new and effective treatment option for patients with advanced prostate cancer.
Phase 1
Recruiting
BAMF Health (+3 Sites)Margaret YuARTBIO Inc.
Image of Carolina Urologic Research Center in Myrtle Beach, United States.

ASP5541 for Prostate Cancer

18+
Male
Myrtle Beach, SC
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems from the hormone therapy. ASP5541 is a different form of AA. It is given as an injection into the muscle. In this study, ASP5541 will be given to men with advanced prostate cancer, both with and without prednisone/prednisolone. This study will check the safety of ASP5541 and compare how well ASP5541 works in men with advanced prostate cancer compared to AA. The main aims of the study are to check how well ASP5541 with prednisone/prednisolone works compared to AA with prednisone/prednisolone in men with advanced prostate cancer who haven't previously been treated with an ARPI, to check safety of ASP5541 given by itself in men with advanced prostate cancer that haven't previously been treated with an ARPI, to check how well ASP5541 given by itself works compared to AA with prednisone/prednisolone in men with advanced prostate cancer that haven't previously been treated with an ARPI, and to check safety of ASP5541 with prednisone/prednisolone in Japanese men with advanced prostate cancer. Adult men with a certain type of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types are: Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow. Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that continues to grow even when testosterone levels are low. In this study there will be 3 treatment groups. In Group 1 men with mCRPC who haven't previously been treated with an ARPI will either be given ASP5541 and prednisone/prednisolone or AA and prednisone/prednisolone. In Group 2 men with mHSPC who haven't previously been treated with an ARPI will either be given ASP5541 by itself or be given AA with prednisone/prednisolone. In Group 3 Japanese men with mCRPC or mHSPC who may or may not have previously been treated with an ARPI will be given ASP5541 with prednisone.
Phase 2
Recruiting
Carolina Urologic Research Center (+1 Sites)Medical MonitorAstellas Pharma Global Development, Inc.
Image of Excel Diagnostics & Nuclear Oncology Center in Houston, United States.

Lutetium-177-PSMA-617 for Prostate Cancer

18+
Male
Houston, TX
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap. The study will enroll up to 30 men with metastatic castration-resistant prostate cancer, with an initial dosing approach that differs from the standard dose. The safety and tolerability of PLUVICTO will be evaluated in this study, with a focus on identifying the optimal dose for this population. This study addresses an important gap in understanding how Pluvicto performs in mCRPC patients with super scan findings.
Phase 2
Recruiting
Excel Diagnostics & Nuclear Oncology CenterEbrahim S. Delpassand, M.D. Chairman & Medical Director, MD., Nuclear Medicine
Have you considered Rubraca clinical trials? We made a collection of clinical trials featuring Rubraca, we think they might fit your search criteria.Go to Trials
Image of Urology Cancer Center PC in Omaha, United States.

Lutetium (177Lu) Vipivotide Tetraxetan + ARPI for Prostate Cancer

18 - 100
Male
Omaha, NE
The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI improves radiographic progression-free survival (rPFS) or time to death compared to AAA617 alone in PSMA-positive mCRPC patients who were previously treated and progressed on ARPI in the biochemical recurrence (BCR)-non metastatic hormone sensitive prostate cancer (mHSPC), mHSPC, or non-metastatic Castration Resistant Prostate Cancer (nmCRPC) setting and have not previously received a taxane-containing regimen in the castrate resistant prostate cancer (CRPC) setting.
Phase 2
Recruiting
Urology Cancer Center PC (+13 Sites)Novartis PharmaceuticalsNovartis Pharmaceuticals
Have you considered Rubraca clinical trials? We made a collection of clinical trials featuring Rubraca, we think they might fit your search criteria.Go to Trials
Image of NEXT Oncology /ID# 261601 in San Antonio, United States.

ABBV-969 for Prostate Cancer

18+
All Sexes
San Antonio, TX
Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 140 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses will be selected from Part 1 and mCRPC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Phase 1
Recruiting
NEXT Oncology /ID# 261601 (+10 Sites)ABBVIE INC.AbbVie
Have you considered Rubraca clinical trials? We made a collection of clinical trials featuring Rubraca, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security